Michael D. Clayman - 19 Jul 2021 Form 4 Insider Report for Flexion Therapeutics Inc

Role
President and CEO, Director
Signature
/s/ Mark S. Levine, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
19 Jul 2021
Net transactions value
$0
Form type
4
Filing time
20 Jul 2021, 20:44:14 UTC
Previous filing
28 Jun 2021
Next filing
19 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FLXN Common Stock Tax liability -13,859 -4% 334,981 19 Jul 2021 Direct F1
holding FLXN Common Stock 373,769 19 Jul 2021 By the Michael D.Clayman 2006 Revocable Trust
holding FLXN Common Stock 24,600 19 Jul 2021 By the Michael D. Clayman Irrevocable Trust
holding FLXN Common Stock 388,683 19 Jul 2021 By Versant Development Fund III, LLC F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on July 16, 2020.
F2 Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.